Parabilis Medicines vs Epic Systems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Epic Systems leads in AI visibility (86 vs 52)
Parabilis Medicines logo

Parabilis Medicines

ChallengerHealthcare & Life Sciences

AI Peptide Therapeutics

Clinical-stage biotech; raised $305M Series F (Jan 2026) for AI-optimized peptides targeting intracellular cancer proteins previously considered undruggable; oncology-first pipeline

AI VisibilityBeta
Overall Score
C52
Category Rank
#302 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
49
Perplexity
54
Gemini
58

About

Parabilis Medicines is a clinical-stage biotechnology company applying AI to the design of peptide-based therapeutics targeting proteins previously considered undruggable, with a primary focus on oncology. The company was founded on the insight that AI-optimized peptides — short chains of amino acids — can be engineered to reach and modulate intracellular protein targets that small molecules and biologics cannot access. Parabilis uses proprietary computational platforms to design, screen, and optimize peptide candidates with improved cell permeability, stability, and target selectivity.\n\nThe company's pipeline is centered on cancer proteins that drive tumor growth but lack conventional binding pockets for small molecule inhibition. Parabilis's AI-designed peptides are engineered to penetrate cancer cells and disrupt these oncogenic interactions, potentially unlocking entirely new therapeutic options for patients with tumors driven by these targets. The approach also has potential applications in other diseases where intracellular protein-protein interactions are central to pathology.\n\nParabilis raised $305M in a Series F round in January 2026, one of the largest biotech fundraises of that period. The financing was designed to advance its lead programs through clinical development and expand its pipeline of AI-designed peptide candidates. With over $300M in fresh capital, Parabilis is one of the most heavily funded companies in the emerging AI peptide therapeutics space, positioning it to compete with both traditional peptide drug developers and newer AI-native biotech platforms.

Full profile
Epic Systems logo

Epic Systems

LeaderHealthcare

EHR Systems

Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.

AI VisibilityBeta
Overall Score
A86
Category Rank
#10 of 596
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
83
Perplexity
83
Gemini
83

About

Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.

Full profile

AI Visibility Head-to-Head

52
Overall Score
86
#302
Category Rank
#10
79
AI Consensus
70
stable
Trend
stable
49
ChatGPT
83
54
Perplexity
83
58
Gemini
83
51
Claude
92
52
Grok
92

Key Details

Category
AI Peptide Therapeutics
EHR Systems
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Parabilis Medicines
AI Peptide Therapeutics
Only Epic Systems
EHR Systems

Integrations

Only Parabilis Medicines

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.